7 employees
Nirogy Therapeutics is focusing on small-molecule drugs that target the solute carrier family of transporter proteins (SLCTs).
2013
$17M
from 2 investors over 2 rounds
Nirogy Therapeutics raised $17M on January 26, 2021
Investors: Sporos Bioventures and -